Lercapin

Lercanidipine, the active ingredient in Lercapin, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle and improving overall arterial compliance.

GNH USA supplies Lercapin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery across multiple continents.

Lercapin (lercanidipine) is a calcium channel blocker used in the management of hypertension. Hypertension: lowers elevated systolic and diastolic blood pressure. Essential hypertension: improves overall blood pressure control. Isolated systolic hypertension: reduces high systolic pressure. Secondary hypertension: serves as adjunct therapy to achieve target blood pressure. High cardiovascular risk patients: incorporated into combination regimens to manage blood pressure effectively.

Lercapin may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness or light‑headedness, especially upon standing. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Angioedema: swelling of face, lips, tongue, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: signs of liver injury. - Anaphylactic reactions: life‑threatening allergic response.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Gradual dose adjustments: avoid abrupt changes that may precipitate hypotension. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: start at lower doses due to increased sensitivity. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors that can raise drug levels. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercapin can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Concomitant antihypertensives (e.g., other calcium channel blockers): risk of excessive hypotension. - Grapefruit juice: can elevate drug exposure.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood pressure‑lowering effect. - Diuretics: may enhance hypotensive response. - Other CYP3A4 substrates: potential alteration of their plasma levels.